All pairs

Lemborexant and Itraconazole

Desk tier: Serious concern

Mechanism: strong CYP3A4 inhibition of clearance (↑ exposure)

“Avoid concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors”
Dayvigo (lemborexant), section 2.2 Dosage Recommendations for Concomitant Use / 7.1. DailyMed label

Open this pair in the desk

All pairs for Lemborexant · Itraconazole

Enzyme behind this pair: CYP3A4

Educational reference only. Not FDA-cleared. The Prescribing Information governs.